secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2023-02-10T23:59:59+00:00
Accession:  0001437749-23-003052
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q2 revenue falls 15.6% YoY; swings to net loss of $55K
---------------------------------------------------------------------------

- Revenue $12.3M vs $14.6M a year ago; operating loss ~$33K vs income $0.7M.
- Net loss of $55K ($0.00 per share) vs net income $1.0M ($0.04) in prior-year quarter.
- Six-month revenue $24.6M (-9.9% YoY); net loss $90K vs income $1.5M.
- Co-CEOs cite customer overstocking during pandemic as primary cause of sales decline.
- Two largest customers in Contract Manufacturing Segment represent ~91% of total revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774923003052/0001437749-23-003052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774923003052/inbp20230209_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-003052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer